YSB (HKG:9885) granted nearly 32.6 million share options to Chair and CEO Buzhen Zhang and CFO Fei Chen under a 2023 incentive plan, according to a Tuesday Hong Kong bourse filing.

Shares of the pharmaceutical retailer were up 15% in Wednesday afternoon trading.

Of the total, over 26 million shares were granted to Zhang and 6.5 million to Chen, representing 3.8% and 0.95% of the firm's issued share capital.

The options are exercisable at HK$4.608 per share within 10 years.

The firm now has a little over 1.5 million shares available for future grant under the non-diluting scheme mandate limit.